EPCAM and neoplasm: Catumaxomab is a targeted immunotherapy that is characterized by its binding to three different cell types: tumor cells; T-cells and accessory cells.1–3 It is composed of mouse and rat immunoglobulin (Ig)G that binds to human EpCAM on tumor cells and human CD3 receptors on T-cells, respectively.